CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 412 target
Drug / intervention
fruquintinib +3 moredrug
Likely dose
paclitaxel 175 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06584032
NCT06584032Phase 3RecruitingOn TrackUpdated 17mo ago
CompareCT.gov

A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer

Hutchmed·interventional·Posted Sep 4, 2024·Updated Jan 7, 2025

In Brief

A Phase 3 clinical trial evaluating fruquintinib, sintilimab, and 2 other interventions for Advanced Endometrial Cancer. Currently recruiting, targeting 412 participants across 17 sites.

Detailed Summary

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Endometrial Cancer
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
20252026202720282029
First PostedSep 4, 2024
Enrollment StartDec 12, 2024
Primary CompletionJan 8, 2029
Study CompletionJun 9, 2029
TodayJul 1, 2026
Enrollment to primary: 4.1 yearsPosted 1.8 years agoPrimary completion in 2.5 years

Interventions

fruquintinibdrug

Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

sintilimabbiological

Sintilimab will be intravenously administrated on Day 1 every three weeks.

paclitaxeldrug

175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

doxorubicindrug

60mg/m\^2 via IV infusion, on Day 1 every three weeks.